Clinical Trials Directory

Trials / Completed

CompletedNCT03311477

A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors

A Phase I Study to Evaluate the Safety and Pharmacokinetics of ABBV-399 in Japanese Subjects With Advanced Solid Tumors

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
9 (actual)
Sponsor
AbbVie · Industry
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

An open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-399 in participants with advanced solid tumors.

Conditions

Interventions

TypeNameDescription
DRUGABBV-399Intravenous infusion

Timeline

Start date
2017-11-06
Primary completion
2019-03-04
Completion
2019-03-04
First posted
2017-10-17
Last updated
2019-03-14

Locations

2 sites across 1 country: Japan

Source: ClinicalTrials.gov record NCT03311477. Inclusion in this directory is not an endorsement.